In a decision published on 27 July, the Brazilian PTO annulled the patent for the drug Myalo, a CBD based medicine marketed by the company Prati-Donaduzzi. As discussed in our previous article on the subject of Patents for Cannabis Products in Brazil, Prati-Donaduzzi...
Cannabis
Cannabis in Brazil: a synopsis of current market
Recent events in Brazil may be seen as further steps in a slowly changing position in the cannabis market across the region. Such change takes place with the background of growing investment in the medicinal benefits of marijuana and other narcotic substances....
The role of ANVISA in cannabis related patents
As mentioned in our previous post on this topic, patent applications for pharmaceutical products or processes must be submitted to ANVISA (The Brazilian Health Surveillance Agency) for prior consent based on a public health analysis. The government lists many...
Patents for cannabis products in Brazil
In a recent post on this topic, we discussed how the slowly changing position toward cannabis-based products in Brazil, with the background of growing investment in the medicinal benefits of marijuana and other narcotic substances. But what is the current position in...
Cannabis products in Brazil: a new agri-business?
Recent events in Brazil may be seen as further steps in a slowly changing position toward cannabis-based products in the region. Such change takes place with the background of growing investment in the medicinal benefits of marijuana and other narcotic substances....